A MedTech targeting early detection of esophageal cancer has raised £32.5m in Series B funding.
Founded by experts at the University of Cambridge, Cyted Health is pioneering the development of minimally invasive cell collection coupled with proprietary biomarker discovery to transform the detection of pre-cancerous, cancerous and inflammatory esophageal conditions.
The round was led by the British Business Bank – which contributed £5m – EQT Life Sciences and Advent Life Sciences, with continued support from existing investors Morningside and BGF.
Cyted’s technology has already demonstrated significant success across the NHS, completing over 35,000 tests and building a robust portfolio of peer-reviewed publications.
The financing will be used to accelerate the commercial expansion of Cyted’s diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic tests.
“Cyted is an excellent example of the kind of high-impact business we aim to back. Their innovation has the potential to transform early cancer detection and create lasting health outcomes both in the UK and globally,” said Carmine Circelli, director, life sciences at British Business Bank.
Ex-Aston Martin CEO’s startup buys Oxford spinout after £5m raise
Marcel Gehrung, CEO and co-founder of Cyted Health, said: “This Series B financing marks a defining moment for Cyted as we continue to deepen our commitment to detecting esophageal diseases earlier.
“This investment will help us consolidate our leading position in the market by expanding our US presence and adding new life-saving innovations to our advanced diagnostics portfolio.”
Executive shake-up at Ultimate Products as founder takes new role